Latest New Zealand News

New Zealand King Salmon reports a 7% revenue decline to NZD 94.5 million and a net loss of NZD 20.8 million for the first half of 2025, suspending dividends amid ongoing challenges.

New Zealand King Salmon reports a $20.8 million net loss for the half-year ending July 2025, driven by biological asset write-downs, while maintaining EBITDA guidance and advancing key growth initiatives.

Cleanaway Waste Management has updated its FY2025 final dividend details, including currency options for New Zealand shareholders and a revised Dividend Reinvestment Plan price.

Liberty Group announces a shift to quarterly unfranked distributions, starting with a 7.5 cents per security interim payment for Q3 2025, signaling confidence in its financial stability.

Australian Unity Limited has launched a $120 million equity raising through a non-underwritten entitlement offer and placement, aiming to strengthen its balance sheet and support strategic acquisitions.

Amplitude Energy has successfully raised $131 million through an institutional entitlement offer and placement, positioning itself to accelerate growth projects including the Nestor prospect and Patricia Baleen restart.

WiseTech Global has updated its dividend announcement, confirming a fully franked ordinary dividend for the half-year ending June 2025 and setting the Dividend Reinvestment Plan price at AUD 96.75.

Newmont Corporation has updated its dividend announcement to clarify currency exchange rates and payment methods for the quarter ending June 2025, affecting how investors receive their returns.

Tower Limited has renewed its FY26 reinsurance programme with lower premium expenses and enhanced catastrophe coverage, signaling strong financial resilience amid evolving risk landscapes.

Commonwealth Bank of Australia updates its final dividend details, confirming a fully franked payout of AUD 2.60 per share and setting the Dividend Reinvestment Plan price at AUD 168.60 with no discount.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

Myer Group posted modest sales growth in FY25, buoyed by the Apparel Brands acquisition, but faced profitability challenges from operational disruptions and macroeconomic pressures. The Group is advancing its omni-channel strategy and cost management initiatives while addressing National Distribution Centre issues.